Insider Selling: Artivion, Inc. (NYSE:AORT) Insider Sells $176,340.67 in Stock

Artivion, Inc. (NYSE:AORT) insider John E. Davis sold 6,457 shares of Artivion stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $176,340.67. Following the completion of the sale, the insider now owns 160,631 shares of the company’s stock, valued at approximately $4,386,832.61. The trade was a 3.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Artivion Stock Performance

NYSE AORT opened at $25.34 on Friday. The firm’s fifty day moving average price is $29.58 and its two-hundred day moving average price is $27.80. The stock has a market cap of $1.06 billion, a PE ratio of -1,267.00 and a beta of 1.75. Artivion, Inc. has a fifty-two week low of $18.38 and a fifty-two week high of $32.33. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88.

Artivion (NYSE:AORT) last posted its earnings results on Monday, February 24th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). The company had revenue of $97.31 million for the quarter, compared to the consensus estimate of $100.82 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. On average, equities analysts expect that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on AORT shares. JMP Securities reissued a “market outperform” rating and issued a $33.00 price objective on shares of Artivion in a research note on Tuesday, December 10th. Needham & Company LLC decreased their price objective on shares of Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday. Stifel Nicolaus decreased their price objective on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Oppenheimer lifted their price objective on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Artivion presently has an average rating of “Buy” and an average target price of $31.40.

Institutional Trading of Artivion

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Squarepoint Ops LLC grew its stake in shares of Artivion by 30.8% during the fourth quarter. Squarepoint Ops LLC now owns 35,707 shares of the company’s stock worth $1,021,000 after buying an additional 8,404 shares during the last quarter. Tidal Investments LLC lifted its holdings in shares of Artivion by 14.5% during the fourth quarter. Tidal Investments LLC now owns 179,806 shares of the company’s stock worth $5,141,000 after purchasing an additional 22,804 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Artivion during the fourth quarter worth $64,000. Point72 Asset Management L.P. acquired a new position in shares of Artivion during the fourth quarter worth $5,573,000. Finally, ProShare Advisors LLC lifted its holdings in shares of Artivion by 44.7% during the fourth quarter. ProShare Advisors LLC now owns 11,924 shares of the company’s stock worth $341,000 after purchasing an additional 3,683 shares during the period. Institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.